Unlock the power of deep, real-world data for evidence generation, market access, and advanced analytics
Harness the full potential of real-world data for pharma. High-quality real-world data (RWD) is critical for generating insights that shape market access strategies, regulatory approvals, payer reimbursement decisions, and commercial success. However, pharma faces ongoing challenges: incomplete datasets, fragmented data, and limited access to longitudinal, patient-level details which hinder the pace in which progress is achieved.
A federated real-world data platform
datma.FED connects pharma with highly detailed, well-structured data from health systems and molecular labs. Unlike traditional datasets that offer only breadth, datma.FED delivers depth, ensuring teams can answer targeted, high-impact research questions.
Generate evidence to support guidelines, payer decisions, and clinical adoption
Map patient journeys to refine market access strategies
Enhance the utility of your existing datasets with missing critical data
Evidence generation: purpose built for targeted research questions
When breadth isn’t enough- depth makes the difference
Some research questions require more than broad datasets alone, they need deep, patient-level insights to generate evidence that supports regulatory submissions, payer engagement, and physician adoption.
With datma.FED, pharma teams gain access to highly granular, real-world patient data, enabling precise, question-driven analyses that go beyond what’s available from other data sources.
Where Depth Matters
Guideline & policy influence
Generate data-backed evidence to support updates in treatment guidelines
Payer & reimbursement strategy
Strengthen arguments with detailed, real-world patient outcomes
Physician awareness & adoption
Demonstrate real-world impact to drive physician confidence
We handle the legwork. You get the insights
datma.FED removes operational barriers to deliver a turnkey evidence generation solution.
By eliminating both data and operational barriers, datma.FED allows you to receive fit-for-purpose RWD tailored to your specific research questions.
Identifying & onboarding the right sites for data sources (health systems, laboratories, etc.)
Recruiting & onboarding the Principal Investigator (PI)
Managing all paperwork, contracts, and agreements
Executing the study from start to finish
Market access: map the full patient journey for informed strategy decisions
Bringing therapies to market requires more than just claims and EHR data. Pharma teams need real-world insights into how patients move through the healthcare system, what barriers prevent timely access to treatment, and how physician prescribing decisions are made.
The challenge: limited visibility into real-world patient journeys
Unclear barriers to treatment adoption
Where are patients dropping off in care pathways?
Limited visibility into physician behavior
How do physicians across different regions and institutions differ in treatment decisions?
Fragmented treatment timelines
What happens between diagnosis, therapy initiation, and long-term follow up?
datma.FED provides a clearer view of patient pathways
Map complete patient pathways
From diagnosis to therapy initiation to long-term outcomes, including real-world treatment sequencing
Analyze physician referral and prescribing trends
Understand how providers in different institutions, geographies, and specialties adopt therapies
Identify treatment drop-off points
Pinpoint where patients face delays, gaps, or discontinuation
Gain a data-driven foundation for improving market access strategies, and ensure the right therapies reach the right patients faster
We analyzed data from over 90,000 oncology patients, identifying 14,000 NSCLC cases using ICD-10 and CPT codes. Using generative AI, we determined the landscape for each NSCLC segment. 40% of NSCLC patients received molecular testing, exceeding the published benchmark of 22%. The MET 14 exon mutation was found in 2.36% of this population, which is aligned with published data at 3-4%.
Only 17% received the targeted therapy Drug A
Analytics teams: augment your existing datasets for more comprehensive insights with ready-to-use RWD
Strengthen your data without replacing it
Analytics teams are responsible for transforming raw data into actionable insights, but traditional datasets often lack key elements needed for complete analysis.
Rather than replacing existing datasets, datma.FED augments your current data assets, filling in gaps with critical missing data to support research, evidence generation, and commercial analytics.
Work with more complete, high-quality datasets, leading to more precise modeling, forecasting, and stronger strategic insights.
Fill gaps in your existing datasets
Enhance your data sources by integrating high-resolution pathology and molecular data
Ready-to-use
Data is harmonized and prepared for immediate use, saving you valuable preparation time
Leverage longitudinal data
Gain deeper insights by tracking patients across extended care timelines
